Chimeric antigen receptor (CAR) T–cell immunotherapy re-engineers a patient’s immune cells to target cancer cells.
Enhanced CAR T-cell homing boosts treatment efficacy for osteosarcoma
- Post author:
- Post published:August 5, 2024
- Post category:uncategorized